Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bcl-2-associated X protein (BAX) and Poly [ADP-ribose] polymerase 1 (PARP1) are two distinct but functionally linked proteins central to the regulation of cell death and DNA integrity. BAX (UniProt Q07812) is a pro-apoptotic member of the Bcl-2 family that, upon activation, translocates to the mitochondria to induce mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and subsequent caspase activation (PubMed: 10733517). PARP1 (UniProt P09874) is a nuclear enzyme primarily involved in the detection and repair of DNA single-strand breaks; however, during apoptosis, it is typically cleaved and inactivated by caspases to conserve cellular energy (PubMed: 7526156). In the context of cancer therapy, PARP1 is a major therapeutic target for PARP inhibitors (e.g., olaparib, rucaparib), which exploit synthetic lethality in tumors with homologous recombination deficiencies, such as BRCA mutations (PubMed: 22556261). While BAX is not yet a common direct clinical target, its expression and activation are frequently used as biomarkers for the efficacy of pro-apoptotic therapies, including those involving PARP inhibition. Together, these molecules serve as critical indicators of a cell's transition from DNA repair to programmed cell death.
PARP inhibitors act by competitively inhibiting the catalytic activity of PARP1 and by trapping the enzyme on damaged DNA, leading to double-strand breaks that are lethal in cells with homologous recombination deficiencies (synthetic lethality). BAX-mediated mechanisms involve the formation of oligomeric pores in the mitochondrial outer membrane (MOMP) to initiate the intrinsic apoptotic pathway, often occurring downstream of DNA damage or as a result of caspase-mediated PARP1 cleavage during the execution phase of cell death.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bcl-2-associated X protein and Poly [ADP-ribose] polymerase 1 (BAX and PARP1).